TEVA · Teva Pharmaceutical Industries Ltd
$36.77
+0.25 (+0.68%)
At close · Aug 14
Market Cap
$42.85B
Shares
1.17B
Teva Pharmaceutical Industries Ltd Earnings Call Transcripts
Every quarterly earnings call for Teva Pharmaceutical Industries Ltd (TEVA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼7.5%
$3.60B
$61.00M
'22 Q3
22-11-03
▼5.3%
$3.88B
−$1.30B
'22 Q4
23-02-08
▲0%
$3.66B
−$220.00M
'23 Q1
23-05-10
▲2.4%
$3.88B
−$872.00M
'23 Q2
23-08-02
▲7.1%
$3.85B
$69.00M
'23 Q3
23-11-08
▲14.8%
$4.46B
$464.00M
'23 Q4
24-01-31
▲4.3%
$3.82B
−$139.00M
'24 Q1
24-05-08
▲7.4%
$4.16B
−$846.00M
'24 Q2
24-07-31
▲12.5%
$4.33B
−$437.00M
'24 Q3
24-11-06
▼5.1%
$4.23B
−$217.00M
'24 Q4
25-01-29
▲1.9%
$3.89B
$214.00M
'25 Q1
25-05-07
▲0.3%
$4.18B
$282.00M
'25 Q2
25-07-30
▲3.4%
$4.48B
$433.00M
'25 Q3
25-11-05
▼64.5%
$1.50B
$481.00M
'25 Q4
26-01-28
▲2.3%
$3.98B
$369.00M
'26 Q1
26-04-29
LATEST
▼0.8%
$4.14B
−$576.00M
'26 Q2
26-07-29
Earnings call
FY26 · Q2
2026-07-29
Q2 2026 Teva Pharmaceutical Industries Ltd. Earnings Conference Call
Confident tone
Pipeline launches (olanzapine, Ecopipam) and milestones
Innovative portfolio growth (Austedo, Ajovy, Uzedy)
Schizophrenia / LAI market opportunity
Revenue
$4.14B
▼ 0.8% YoY Diluted EPS
$-0.49
▼ 304.2% YoY Gross margin
52.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Goldman Sachs Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-29
Teva Pharmaceutical Industries Ltd Q1 FY2026 Earnings Call
Confident tone
Innovative Portfolio Growth (AUSTEDO, UZEDY, AJOVY)
Emalex Bioscience Acquisition / Ecopipam
R&D Pipeline and Readouts
Revenue
$3.98B
▲ 2.3% YoY Diluted EPS
$0.31
▲ 72.2% YoY Gross margin
49.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-10
Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-09
Leerink Partners Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-01-28
Teva Pharmaceutical Industries Ltd Q4 FY2025 Earnings Call
Confident tone
Innovative portfolio growth
Pipeline and R&D execution
Business development and capital allocation
Revenue
$1.50B
▼ 64.5% YoY Gross margin
177.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-13
44th Annual J.P. Morgan Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-05
Teva Pharmaceutical Industries Ltd Q3 FY2025 Earnings Call
Confident tone
Innovative portfolio growth engines (AUSTEDO, UZEDY, AJOVY)
AUSTEDO CMS price negotiation and 2027 targets
Cost savings program and operational efficiency
Revenue
$4.48B
▲ 3.4% YoY Diluted EPS
$0.37
Gross margin
51.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Teva Pharmaceutical Industries Ltd Q2 FY2025 Earnings Call
Confident tone
Innovative portfolio growth
Generics business performance
R&D pipeline and innovation
Revenue
$4.18B
▲ 0.3% YoY Diluted EPS
$0.24
Gross margin
50.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Teva Pharmaceutical Industries Ltd Q1 FY2025 Earnings Call
Confident tone
Innovative brands growth
Long-acting injectable franchise in schizophrenia
2027 strategic targets and Pivot to Growth
Revenue
$3.89B
▲ 1.9% YoY Diluted EPS
$0.18
Gross margin
48.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2025-02-24
Duvakitug (Anti-TL1A) Phase 2b additional data presentation after ECCO – Conference call
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q4
2025-01-29
Teva Pharmaceutical Industries Ltd Q4 FY2024 Earnings Call
Confident tone
Financial performance and guidance
Innovative medicines (AUSTEDO, AJOVY, UZEDY)
Late-stage pipeline
Revenue
$4.23B*
▼ 5.1% YoY Gross margin
50.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Teva Pharmaceutical Industries Ltd Q3 FY2024 Earnings Call
Confident tone
Innovative portfolio growth (AUSTEDO, AJOVY, UZEDY)
TAPI divestment
Generics business
Revenue
$4.33B
▲ 12.5% YoY Diluted EPS
$-0.39
▼ 750% YoY Gross margin
49.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Teva Pharmaceutical Industries Ltd Q2 FY2024 Earnings Call
Confident tone
R&D pipeline progress (Olanzapine, TL1A, ICS/SABA, MSA)
AUSTEDO performance and IRA considerations
Innovative portfolio: AJOVY, UZEDY, SIMLANDI
Revenue
$4.16B
▲ 7.4% YoY Diluted EPS
$-0.75
Gross margin
48.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Teva Pharmaceutical Industries Ltd Q1 FY2024 Earnings Call
Confident tone
Biosimilars Launches and Outlook
AUSTEDO Growth and Guidance
Olanzapine LAI Phase III Results
Revenue
$3.82B
▲ 4.3% YoY Diluted EPS
$-0.12
Gross margin
46.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-31
Teva Pharmaceutical Industries Ltd Q4 FY2023 Earnings Call
Confident tone
Innovative brands: Austedo and Ajovy
New product launches (Uzedy, biosimilars)
Pivot to Growth strategy execution and 2023 results
Revenue
$4.46B*
▲ 14.8% YoY Gross margin
54.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Teva Pharmaceutical Industries Ltd Q3 FY2023 Earnings Call
Revenue
$3.85B
▲ 7.1% YoY Diluted EPS
$0.06
▲ 20% YoY Gross margin
48.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Teva Pharmaceutical Industries Ltd Q2 FY2023 Earnings Call
Revenue
$3.88B
▲ 2.4% YoY Diluted EPS
$-0.78
Gross margin
46.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Teva Pharmaceutical Industries Ltd Q1 FY2023 Earnings Call
Revenue
$3.66B
▲ 0% YoY Diluted EPS
$-0.20
Gross margin
43.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-08
Teva Pharmaceutical Industries Ltd Q4 FY2022 Earnings Call
Revenue
$3.88B*
▼ 5.3% YoY Diluted EPS
$-1.17
Gross margin
45.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Teva Pharmaceutical Industries Ltd Q3 FY2022 Earnings Call
Revenue
$3.60B
▼ 7.5% YoY Diluted EPS
$0.05
▼ 80.8% YoY Gross margin
46.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-27
Teva Pharmaceutical Industries Ltd Q2 FY2022 Earnings Call
Revenue
$3.79B
▼ 3.2% YoY Diluted EPS
$-0.23
▼ 221.1% YoY Gross margin
47.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Teva Pharmaceutical Industries Ltd Q1 FY2022 Earnings Call
Revenue
$3.66B
▼ 8.1% YoY Diluted EPS
$-0.86
▼ 1328.6% YoY Gross margin
47.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-09
Teva Pharmaceutical Industries Ltd Q4 FY2021 Earnings Call
Revenue
$4.10B*
▼ 8% YoY Gross margin
50.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Teva Pharmaceutical Industries Ltd Q3 FY2021 Earnings Call
Revenue
$3.89B
▼ 2.3% YoY Diluted EPS
$0.26
Gross margin
46.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Teva Pharmaceutical Industries Ltd Q2 FY2021 Earnings Call
Revenue
$3.91B
▲ 1% YoY Diluted EPS
$0.19
▲ 46.2% YoY Gross margin
47.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Teva Pharmaceutical Industries Ltd Q1 FY2021 Earnings Call
Revenue
$3.98B
▼ 8.6% YoY Diluted EPS
$0.07
▲ 16.7% YoY Gross margin
47.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-10
Teva Pharmaceutical Industries Ltd Q4 FY2020 Earnings Call
Revenue
$4.45B
▼ 0.3% YoY Diluted EPS
$0.14
▲ 40% YoY Gross margin
46.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Teva Pharmaceutical Industries Ltd Q3 FY2020 Earnings Call
Revenue
$3.98B
▼ 2.8% YoY Diluted EPS
$-3.97
Gross margin
46.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Teva Pharmaceutical Industries Ltd Q2 FY2020 Earnings Call
Revenue
$3.87B
▼ 7.3% YoY Diluted EPS
$0.13
Gross margin
45.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Teva Pharmaceutical Industries Ltd Q1 FY2020 Earnings Call
Revenue
$4.36B
▲ 5% YoY Diluted EPS
$0.06
Gross margin
47.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-12
Teva Pharmaceutical Industries Ltd Q4 FY2019 Earnings Call
Revenue
$4.47B
▲ 1.1% YoY Diluted EPS
$0.10
Gross margin
43.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 earnings calls
Key facts
CIK
818686
CUSIP
881624209
13F (30d)
616 filings
600 filers
Visit website
Investor relations